CCL2 and neoplasm: Additionally, trabectedin inhibits the production of specific inflammatory mediators in macrophages, such as IL-6 and C-C motif ligand 2 (CCL2), which likely contributes to the depletion of the TAM pool in the tumor microenvironment [153].